amifampridine has been researched along with Motor Neuron Disease in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Motor Neuron Disease: Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome." | 2.76 | Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases. ( Bertorini, TE; Igarashi, M; Li, YD; Rashed, H; Tolley, EA; Zeno, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertorini, TE | 1 |
| Rashed, H | 1 |
| Zeno, M | 1 |
| Tolley, EA | 1 |
| Igarashi, M | 1 |
| Li, YD | 1 |
1 trial available for amifampridine and Motor Neuron Disease
| Article | Year |
|---|---|
Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cross-Over Studies; Double-Blind Met | 2011 |